MISSION Empowering healthcare and pharmaceutical leaders with innovative ctDNA solutions to enable precise, data-driven cancer monitoring and better patient outcomes.
VISION We envision a future where cancer is a curable disease. By advancing personalised ctDNA monitoring, we aim to empower healthcare providers and researchers with the tools to detect, monitor, and treat cancer with unmatched precision, bringing us closer to a world free from its burden.
SIMSEN DIAGNOSTICS
Team Members
CEO
Pontus Rehn
Pontus Rehn has over 20 years of experience in commercial leadership roles in the medical device and IVD industries, including global and regional positions like VP Market Development, Chief Commercial Officer, and Director of Commercial Strategy. SCHEDULE a call with Pontus below!
CTO
Stefan Filges
Stefan Filges, an accomplished bioinformatician with a Ph.D. in ultrasensitive sequencing, became part of Simsen Diagnostics in 2022. He played a crucial role as a co-author in the original publication of SiMSen-Seq, which was published in Nature Protocols.
QA/RA Manager
Jonna Eriksson
Jonna Eriksson holds a Ph.D. in genomics, bioinformatics, botany and evolution and has extensive experience from quality management and regulatory policies. Previous roles include Ass. Prof. at University of Skövde and Sr. R&D researcher at TATAA Biocenter.
Research Engineer
Niki Rostamzadeh
Niki Rostamzadeh leverages his prior experience with founder Anders Ståhlberg’s team, bringing a deep understanding of our technology to his current role. As our Research Engineer, he is responsible for managing R&D experiments and overseeing the handling of customer samples.
Schedule a Zoom meeting
BOARD OF DIRECTORS
Board Directors
Chair of the Board
Daniel Poté
Daniel Poté is employed as a business developer at GU Ventures. He has a solid and relevant background, having previously served as CEO of Predicare AB, CEO of Emotra AB, and held other senior positions within medical technology and biotechnology companies.
Board Director
Artur Aira
Artur is the CEO of Active Health. He is an experienced leader with more than 25 years of experience from pharma, diagnostics and biotechnology companies. Previous positions include CEO of Abigo Medical and SVP and BA manager of BICO. In addition, Artur has served on more than 30 company boards.
Board Director
Tony Godfrey
Tony Godfrey is professor at the Department of Surgery and Computational Biomedicine at Boston University School of Medicine. Tony co-invented SiMSen-Seq and developed further improvements of the technique. In addition, Tony has been an associate professor at several well-known universities in the US, such as the University of Rochester, The Mount Sinai Hospital, and the University of Pittsburgh.
Board Director
Jan Erik Smith
Jan Erik Smith works currently as Vice President at Circius Pharma and represents Gobia Enterprises, as well as is on the boards of several of the Gobia portfolio companies. He has previously held international roles within the medical technology companies Getinge Group and ABIGO Medical. Jan Erik holds a Master of Science degree in Business Administration from Lund University.
Board Director
Erik Brobjer
Erik has a background from AstraZeneca, Novartis and Mölnlycke Healthcare in sales, marketing and business development. Erik is an advisor at Gobia Enterprises and also Chief Commercial Officer at Circius Pharma. Erik has a Master of Science in Business Administration from the University of Gothenburg. Erik sits on the board of Dx4Life.
SIMSEN DIAGNOSTICS
Company history
2017
SiMSen-Seq published
The SimSen-Seq method published in Nature Protocols
2020
Simsen is founded
The inventors, Prof. Anders Ståhlberg and Prof. Tony Godfrey, decide to incorporate the company that will commercialise their invention - SiMSen-Seq. They founded the company together with Prof. Mikael Kubista and GU Ventures.
2021
Business begins
A 50 mSEK Vinnova grant was awarded and the company's first CEO and yet only employee was hired. Additional patent applications were submitted. Lab established at Sahlgrenska Science Park.
2022
Customers!
First customers sign on. A mix of research hospitals, and international diagnostics companies as well as pharmaceutical companies.
2023
Company Milestone
The office and lab moves to AstraZeneca's BioVentureHub in Mölndal on the outskirts of Gothenburg, Sweden.
2024
Growth
More customers sign on, including the first private cancer clinic. A new CEO is hired. A comprehensive QMS and GDPR framework is developed. A clear growth plan, including international expansion, is being commenced!
